Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PGR | P06401 | 6/20 | 0.43 |
| ▸ | IP6K1 | Q92551 | 6/20 | 0.43 |
| ▸ | IP6K3 | Q96PC2 | 1/20 | 0.43 |
| ▸ | IP6K2 | Q9UHH9 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 2/20 | 0.43 |
| ▸ | HTR1A | P08908 | 2/20 | 0.41 |
| ▸ | HTR2A | P28223 | 2/20 | 0.41 |
| ▸ | HTR7 | P34969 | 2/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.41 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22271500 | 0.87 | PGR (0.53) | PGRIP6K1IP6K3IP6K2CA9 | |
| SCHEMBL20269069 | 0.84 | PGR (0.55) | PGRIP6K1 | |
| SCHEMBL16830171 | 0.84 | PGR (0.55) | PGRIP6K1 | |
| SCHEMBL31430234 | 0.84 | ADRA2B (0.50) | PGRIP6K1IP6K3IP6K2HTR1A | |
| SCHEMBL26025725 | 0.84 | PGR (0.55) | PGRIP6K1IP6K3IP6K2HTR1A | |
| SCHEMBL2213581 | 0.84 | ADRA2B (0.50) | PGRIP6K1IP6K3IP6K2HTR1A | |
| SCHEMBL12598497 | 0.83 | PGR (0.56) | PGR | |
| SCHEMBL8320710 | 0.81 | AKR1B1 (0.49) | PGRIP6K1IP6K3IP6K2MET | |
| SCHEMBL24508357 | 0.80 | IP6K1 (0.67) | PGRIP6K1IP6K3IP6K2HTR1A | |
| SCHEMBL25900353 | 0.80 | PGR (0.55) | PGRIP6K1IP6K3IP6K2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817310-A1 | (SPIROCYCLYLAMIDO) AMINOTHIOPHENE COMPOUNDS AS C-KIT PROTO-ONCOGENE INHIBITORS | OSI Pharmaceuticals, Inc. (US) | 2007-08-15 | — | — | EP | disclosed |
| WO-2006034015-A1 | (SPIROCYCLYLAMIDO) AMINOTHIOPHENE COMPOUNDS AS C-KIT PROTO- ONCOGENE INHIBITORS | OSI PHARMACEUTICALS, INC. (US) | 2006-03-30 | — | — | WO | disclosed |
| US-20060063791-A1 | (Spirocyclylamido)aminothiophene compounds | OSI PHARMACEUTICALS, INC. | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063791-A1 | (Spirocyclylamido)aminothiophene compounds | KIT, BRDT, MALT1 | PGR 887/4885IP6K1 4158/4885IP6K3 4034/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.